Does this have anything to do with Powerfull
Plant Derived Compound
Aimed At Reducing Body Fat and Increasing Lean Muscle
BDC 03, PhytoMedical’s first plant derived compound from the muira puama plant, has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in animal studies, which resulted in the issuance of US patent # 5,516,516.
Native to the Brazilian Amazon and other parts of the Amazon rainforest, the muira puama plant has long been used by indigenous people for the treatment of asthenia, dyspepsia, menstrual disturbances, chronic rheumatism, sexual impotence, ataxia and central nervous system disorders.
Learning of the indigenous uses, early European explorers brought the plant back to Europe, where it became part of herbal medicine for the treatment of impotence, infertility, neurasthenia, menstrual disturbances, hookworms, rheumatism and dysentery. Today, muira puama, with no known health risks associated with its use and no known drug or nutrient interactions, is still listed in the British Herbal Pharmacopoeia, a noted source of herbal medicine.
Pure scientific interest into muira puama’s efficacy and pharmacological properties dates back to the early 1920s, when researchers discovered a bark and root system rich in fatty acids, fatty acid esters, essential oils, plant sterols and triterpenes. More recent studies have indicated that the plant’s active constituents include novel alkaloids, free long chain fatty acids, sesquiterpenes and monoterpenes.
Muira puama’s various ethnobotanical claims by indigenous people have been well documented and researched, including two human trails in France that confirmed that muira puama was effective in improving libido and treating erectile dysfunction. Other clinical research has reported to have in vivo adaptogenic, antifatigue, antistress and CNS effects in humans and animals, as well as animal studies that demonstrated that an extract of muira puama was effective at reducing body fat and cholesterol levels, as well as increasing lean body mass. The latter studies, conducted by noted research scientist Dr. Bruce Cherksey, resulted in a US patent being issued, to which PhytoMedical Technologies has an exclusive worldwide license.
The two most important therapeutic components covered under PhytoMedical’s licensed muira puama based patent – decreasing body fat and increasing lean body mass – directly impact two of the leading causes of mortality in North America, obesity and cachexia.
In determining the efficacy of the muira puama derived composition, animal studies were conducted using Wistar rats (mean weight of 230 grams). Randomly divided into four groups of six rats, two of the groups were allowed to feed at will, while the other two received a restricted amount of food. One group of rats each from the ad libitum and calorie restricted food populations received a daily dose of the patented muira puama derived composition, while the other remaining two groups served as the control, each receiving an equal amount of sesame oil on a daily basis.
After approximately four weeks, rat body weights and perirenal pad weights were measured, as well as blood chemistry analyzed. As expected, restricted food animals showed lower body weight gains than the ad libitum fed animals (about 50 grams versus 160 gram gains). In the ad libitum groups, both the group that received the muira puama derived composition and the one that did not showed virtually the same weight gain (161 grams versus 162 grams). When compared to the calorie restricted animals, the group receiving the muira puama derived composition gained slightly more weight than the group not receiving the composition, however, the difference (55 grams versus 46 grams) was statistically insignificant.
The fat gain versus lean body mass gain in the animals was measured by weighing the perirenal fat pads. In the ad libitum groups, the control animals had perirenal fat pad weights of 1.25 grams, while the muira puama treated animals had pad weights of .96 grams. The perirenal fat pad weight in the calorie restricted groups was approximately .45 grams for both the muira puama composition group and the control group.
These results demonstrate that, in ad libitum fed animals showing overall weight gain, the muira puama derived composition had the effect of decreasing the deposition of fat, while at the same time shifting the overall weight gain towards lean body mass gain.
Additionally, blood chemistry analysis showed a substantial reduction in total cholesterol levels in muira puama treated animals, both in the ad libitum (25% reduction) and restricted diet (15% reduction) populations. In all cases, the cholesterol/HDL ratios were not altered. Further blood chemistry analyses show minimal effect on blood urea nitrogen and creatinine levels in muira puama treated animals, which is consistent with the preservation or anabolism of muscle.
PHYTOMEDICAL TECHNOLOGIES, INC.
